TOPICS
Marketing Attribution for Biotech & Pharma
DIRECT ANSWER
Marketing attribution is the process of assigning credit for a sale or conversion to one or more marketing touchpoints a customer encountered before converting. Models range from single-touch (first or last click) to algorithmic multi-touch, with accuracy improving as data volume and measurement sophistication increase. For Biotech & Pharma companies, this matters because Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch.
What marketing attribution means for Biotech & Pharma
The MLR bottleneck is the defining pain. Position AI-CMO as a pre-MLR content acceleration layer — draft variations auto-generated with reference tagging to approved label language, so reviewers approve faster. Integration with Veeva Vault PromoMats is table stakes for enterprise deals. Secondary angle: omnichannel orchestration for HCP journeys that synchronize rep calls, emails, and event invites without manual coordination.
For Biotech & Pharma teams the relevant marketing pains are: Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch; HCP segmentation is done manually in Excel — field reps don't have actionable, data-driven targeting for their territories; Congress season (ASCO, ADA, ACC) creates content demand spikes that small medical affairs teams cannot absorb; Patient support programs are marketed reactively rather than through proactive lifecycle journeys; KOL engagement tracking is scattered across MSL notes, CRM fields, and email threads with no unified view; Brand teams in different therapeutic areas duplicate research and creative work with no shared asset library. FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute
Attribution Models and Their Trade-offs
The six core attribution models are: last-touch (100% credit to the final touchpoint), first-touch (100% to the first), linear (credit split evenly), time-decay (more credit to recent touches), position-based (U-shaped: 40% first, 40% last, 20% middle), and data-driven (algorithmic, trained on your actual conversion paths). Last-touch is the default in most ad platforms and consistently overstates the role of bottom-funnel paid search.
Data-driven attribution requires a minimum conversion volume — Google Ads needs roughly 3,000 conversions per month across the conversion action for its model to stabilize. Below that threshold, position-based is usually the most defensible manual model. B2B companies with long sales cycles (60–180 days) often need account-level multi-touch attribution layered over CRM data because session-based models break on multi-session, multi-stakeholder journeys.
Running marketing attribution for Biotech & Pharma with CoMo
CoMo's agents apply marketing attribution across HCP email, med-ed portals, LinkedIn, congresses/events, speaker programs, rep-triggered digital, patient advocacy partnerships for Biotech & Pharma companies — tuned to VP Commercial Marketing at mid-size pharma; Director of Marketing Excellence at specialty biotech; Head of Omnichannel at large pharma and run under your approval, alongside every other marketing function.
FAQ
Marketing Attribution for Biotech & Pharma — common questions
Which attribution model should I use?
Start with position-based (U-shaped) if you lack the volume for data-driven. If you run high-volume paid campaigns, switch to data-driven attribution inside your ad platform. For strategic budget decisions, layer in a media mix model — platform attribution systematically overclaims for channels it can measure directly.
How does marketing attribution differ for Biotech & Pharma companies?
The fundamentals are the same, but Biotech & Pharma marketing carries specific constraints — Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch and FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute. CoMo adapts execution to that context automatically.
BUILT BY COMO'S AGENTS
This page was written by CoMo — the autonomous CMO.
CoMo runs every channel of your marketing on your live data. See it work on your brand.